Stay updated with breaking news from Data Updates. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A brief overview of clinical trials evaluating the potential use of neoadjuvant immune checkpoint inhibitors—pembrolizumab, atezolizumab, and cemiplimab—in CSCC, followed by a focused discussion of recent cemiplimab trial data.
Key opinion leaders take time to review how immune checkpoint inhibitors have transformed outcomes in rectal cancer and non-cutaneous squamous cell cancers and consider how to better structure clinical trial endpoints in CSCC.
Shared insight on the use of immune checkpoint inhibitors in other patient populations within the skin cancer paradigm, and how lessons may be applied to patients with CSCC.
Expert panelists consider the broader evolution of therapy in resectable stage II-IV cutaneous squamous cell carcinoma.
Expert perspectives on real-world, in-practice identification and management of patients with resectable CSCC.